US Companies Launch CRISPR Clinical Trial
US Companies Launch CRISPR Clinical Trial
The Germany-based study will test an ex vivo genome-editing therapy for the inherited blood disorder β-thalassemia.
US Companies Launch CRISPR Clinical Trial
US Companies Launch CRISPR Clinical Trial

The Germany-based study will test an ex vivo genome-editing therapy for the inherited blood disorder β-thalassemia.

The Germany-based study will test an ex vivo genome-editing therapy for the inherited blood disorder β-thalassemia.

genome editing
US Companies Launch CRISPR Clinical Trial
US Companies Launch CRISPR Clinical Trial
Catherine Offord | Sep 3, 2018
The Germany-based study will test an ex vivo genome-editing therapy for the inherited blood disorder β-thalassemia.
Gene Editing Reduces Monkeys’ Cholesterol
Gene Editing Reduces Monkeys’ Cholesterol
Ashley Yeager | Jul 10, 2018
The results could lead to a treatment to lower cholesterol in patients with hypercholesterolemia.
CRISPR Efficiency Tied to Cancer-Causing Process
CRISPR Efficiency Tied to Cancer-Causing Process
Kerry Grens | Jun 11, 2018
Two studies find the genome-editing technique works best when cells have a faulty DNA-damage response that’s frequently present in cancers.  
New Methods to Detect CRISPR Off-Target Mutations
New Methods to Detect CRISPR Off-Target Mutations
Sandeep Ravindran | Mar 1, 2018
Researchers have developed a variety of techniques to detect when CRISPR misses the mark.
Immunity May Make CRISPR-Based Therapies Ineffective
Immunity May Make CRISPR-Based Therapies Ineffective
Jim Daley | Jan 10, 2018
Researchers identify antibodies for two commonly used Cas9 proteins in human blood. Investors take notice.
Meet the Press, 1967
Meet the Press, 1967
Kerry Grens | Dec 1, 2017
Fifty years ago, Arthur Kornberg announced to reporters that his team had synthesized functional DNA.
2017 Top 10 Innovations
2017 Top 10 Innovations
The Scientist Staff | Dec 1, 2017
From single-cell analysis to whole-genome sequencing, this year's best new products shine on many levels.
Man Receives First In Vivo Gene-Editing Therapy
Man Receives First In Vivo Gene-Editing Therapy
Kerry Grens | Nov 15, 2017
The 44-year-old patient has Hunter syndrome, which doctors hope to treat using zinc finger nucleases.
RNA Editing Possible with CRISPR-Cas13
RNA Editing Possible with CRISPR-Cas13
Ruth Williams | Oct 25, 2017
Scientists extend the capabilities of the CRISPR-Cas system to include precise manipulations of RNA sequences in human cells.
Base Editing Now Able to Convert Adenine-Thymine to Guanine-Cytosine
Base Editing Now Able to Convert Adenine-Thymine to Guanine-Cytosine
Catherine Offord | Oct 25, 2017
With the arrival of a new class of single-nucleotide editors, researchers can target the most common type of pathogenic SNP in humans.